Sanders to unveil rule requiring drug companies to set fair prices

Sanders to unveil rule requiring drug companies to set fair prices

Sen. Bernie SandersBernard (Bernie) SandersOvernight Health Care: States fight Trump on non-ObamaCare plans | Analysis looks into surprise medical bills | Left hits industry group working against single payer Overnight Energy: Trump Cabinet officials head west | Zinke says California fires are not 'a debate about climate change' | Perry tours North Dakota coal mine | EPA chief meets industry leaders in Iowa to discuss ethanol mandate Sen. Sanders blasts Zinke: Wildfires 'have everything to do with climate change' MORE (I-Vt.) will unveil a new rule forcing pharmaceutical companies to set reasonable prices for drugs developed using research funded by federal research dollars, Huffington Post reported Monday.

The rule — an amendment to the Federal Food, Drug, and Cosmetic Act — is Sanders’s newest attempt to block pharmaceutical company Sanofi Pasteur from receiving a license to develop a vaccine for the Zika virus with the U.S. Army.

Sanofi Pasteur is pursuing a patent that would block other drugmakers from being able to produce and sell the vaccine at a lower price.

ADVERTISEMENT
The French company has received $43 million from the Department of Health and Human Services and is expecting $130 million more for future testing of the drug if current trials are successful. 

Sanders told HuffPost that federal agencies and nonprofits that receive federal funds would have to get manufacturers to sign a reasonable pricing agreement before handing over the exclusive rights to drugs or vaccines.

“The days of allowing Sanofi and other drug makers to gouge American consumers after taking billions in taxpayer money must end,” Sanders said. “That is why I am introducing legislation to demand fairer, lower prices for the Zika vaccine and for every drug developed with government resources. This is a fight that we cannot afford to lose.”

Sanders has attacked the French drugmaker before for its exclusive deal with the Army on the vaccine, calling for President Trump to shut down the deal in a May op-ed for The New York Times.